6533b824fe1ef96bd1280a24

RESEARCH PRODUCT

Beta-adrenoceptor density and subtype distribution in cerebellum and hippocampus from patients with Alzheimer's disease

Björn LemmerThomas G. OhmJürgen BohlLudger Langer

subject

MaleCerebellummedicine.medical_specialtyAdrenergic beta-AntagonistsHippocampal formationTritiumBinding CompetitiveHippocampusPropanolaminesAdenylyl cyclaseBasal (phylogenetics)chemistry.chemical_compoundDegenerative diseaseAlzheimer DiseaseCerebellumInternal medicineReceptors Adrenergic betamedicineHumansHippocampus (mythology)AgedAged 80 and overPharmacologybusiness.industryImidazolesAntagonistGeneral MedicineMiddle Agedmedicine.diseaseKineticsmedicine.anatomical_structureEndocrinologychemistryDementiaFemaleAlzheimer's diseasebusiness

description

beta-Adrenoceptor density and beta 1- and beta 2-subtype distribution were examined in hippocampi and cerebella from patients with Alzheimer's disease (AD/SDAT). Tissues from age-, sex and post-mortem delay matched non-demented patients served as controls. The total beta-adrenoceptor density as evaluated in saturation experiments with the hydrophilic radioligand [3H]CGP 12177 was higher in hippocampal (36-39 fmol/mg protein) than cerebellar tissues (20-21 fmol/mg), however, no differences were found in either brain region between AD/SDAT patients and controls. Subtype distribution using the highly selective beta 1-adrenoceptor antagonist CGP 20712A revealed a slightly higher proportion of beta 1-adrenoceptors in hippocampus (26%-27%) than in cerebellum (20%-21%) with, again, no difference between AD/SDAT and controls. We recently described a 40% reduction in basal and stimulated adenylyl cyclase activity in post-mortem hippocampus of AD/SDAT patients, a brain region greatly affected by the disease, the present data now demonstrate that this disease-related effect is not mirrored by a similar change in beta-adrenoceptor density nor in subtype distribution.

https://doi.org/10.1007/bf00169270